Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Am J Prev Med. 2017 Jan 3;52(4):499–506. doi: 10.1016/j.amepre.2016.11.005

Figure 1. MI-GENES study design.

Figure 1

Notes: The Myocardial Infarction (MI-GENES) study was designed to determine the impact of genetic risk score (GRS) disclosure on clinical and psychosocial outcomes in residents of Olmsted County, Minnesota. Participants aged 45-65 years, with no history of statin use or coronary heart disease (CHD), and at intermediate risk for CHD based on a 10-year risk of 5-20% using the Framingham risk score (or conventional risk score; CRS) received their CRS or their CRS and a GRS based on 28 CHD variants. CRS and GRS were disclosed in conversations with a genetic counselor. This was followed by shared decision-making with a physician, to discuss potential initiation of statin therapy for high-risk patients.